Progressive fibrosing interstitial lung diseases (ILDs) involve similar pathophysiological processes, indicating the potential for common approaches to treatment. Nintedanib (Ofev<sup>®</sup>), an intracellular tyrosine kinase inhibitor (TKI) with antifibrotic properties, was one of the first drugs ...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!